Phosphorsaeure-phenylester-amid | 45951-59-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Phosphorsaeure-phenylester-amid
• 英文别名: Dihydroxy-imino-phenoxy-lambda5-phosphane；dihydroxy-imino-phenoxy-λ5-phosphane
• CAS: 45951-59-5
• 化学式: C₆H₈NO₃P
• 分子量: 173.108
• InChiKey: AXBNYODFUODRIL-UHFFFAOYSA-N

物化性质

• 沸点：
  329.2±25.0 °C(Predicted)
• 密度：
  1.415±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Phosphorsaeure-phenylester-amid 、 水 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Anschuetz; Emery, Justus Liebigs Annalen der Chemie, 1889, vol. 253, p. 118

  摘要：

  DOI：
• 作为产物：
  描述：

  磷酸单苯酯 生成 Phosphorsaeure-phenylester-amid
  参考文献：
  名称：

  Cramer,F.; Wittmann,R., Chemische Berichte, 1961, vol. 94, p. 328 - 337

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE<br/>[FR] INHIBITEURS D'EGFR ET/OU DE HER2 ET PROCÉDÉS D'UTILISATION
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2019046775A1

  公开（公告）日：2019-03-07

  The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.

  该申请涉及一种具有公式X的化合物：该化合物调节HER2和/或其突变体以及/或EGFR和/或其突变体的活性，一种包含该化合物的药物组合物，以及一种治疗或预防HER2和/或其突变体以及/或EGFR和/或其突变体发挥作用的疾病的方法。
• Noncardiotoxic pharmaceutical compounds
  申请人：Barbeau L. Donald

  公开号：US20060035863A1

  公开（公告）日：2006-02-16

  The present invention relates to novel noncardiotoxic compounds and pharmaceutical compositions useful in the treatment of a variety of disorders including the treatment of depression, allergies, psychoses, cancer and gastrointestinal disorders. In particular, the present invention describes pharmaceutical compositions that mitigate life-threatening arrhythmias such as torsade de pointes. Torsade de pointes is a particular cardiac problem associated with many therapeutic agents and has been implicated as a possible cause of sudden death, particularly in those individuals with a past history of disturbances of cardiac rhythm, myocardial infarction, congenital repolarization abnormalities and cardiac risk factors such as hyperlipidemia and age. This arrhythmia is a variant of paroxysmal ventricular tachycardia associated with a prolonged QTc interval or prominent U waves on the ECG. Torsade de pointes is potentially lethal because it can progress to ventricular fibrillation, life-threatening arrhythmias or precipitate sudden death.

  本发明涉及新型无心脏毒性化合物和药物组合物，用于治疗包括抑郁症、过敏、精神病、癌症和胃肠道疾病在内的各种疾病。具体而言，本发明描述了可以缓解危及生命的心律失常，例如扭转型尖波。扭转型尖波是与许多治疗剂相关的一种特殊心脏问题，已被指认为可能导致猝死的原因，特别是在那些有心脏节律紊乱、心肌梗死、先天性复极异常和心脏危险因素（如高脂血症和年龄）的个体中。这种心律失常是一种与心电图上QTc间期延长或U波显著的室性心动过速变异有关的心律失常。扭转型尖波有潜在致命性，因为它可能发展为室颤、危及生命的心律失常或引发猝死。
• [EN] N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL] -L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION<br/>[FR] ESTER DE N-[(2 ' R) -2' -DÉSOXY-2' -FLUORO-2' -MÉTHYL-P-PHÉNYL-5' -URIDYLYL]-L-ALANINE 1-MÉTHYLÉTHYLE ET SON PROCÉDÉ DE PRODUCTION
  申请人：PHARMASSET INC

  公开号：WO2010135569A1

  公开（公告）日：2010-11-25

  Disclosed herein are nucleoside phosphoramidates of formula 4 and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. Disclosed is also a process for preparing compound represented by formula 4: (Formula 4) wherein P* represents a chiral phosphorus atom, which comprises: a) reacting an isopropyl-alanate, (Formula A), a di-X'-phenylphosphate, (Formula B), 2'-deoxy-2f-fluoro-2'-C-methyluridine, (Formula 3), and a base to obtain a first mixture comprising 4; wherein X is a conjugate base of an acid, n is 0 or 1, and X' is a halogen, b) reacting the first mixture with a protecting compound to obtain a second mixture comprising 4; and c) optionally subjecting the second mixture to crystallization, chromatography or extraction in order to obtain 4.

  本文披露了化学式4的核苷酸磷酰胺及其作为治疗病毒性疾病的药物的用途。这些化合物是RNA依赖性5RNA病毒复制的抑制剂，可作为HCV NS5B聚合酶的抑制剂，HCV复制的抑制剂以及哺乳动物丙型肝炎感染的治疗药物。还披露了一种制备化合物4的方法：（化学式4），其中P*代表手性磷原子，包括：a）反应异丙基-丙氨酸酯（化学式A）、二-X'-苯基磷酸酯（化学式B）、2'-脱氧-2f-氟-2'-C-甲基尿嘧啶（化学式3）和碱以获得含有4的第一混合物；其中X是酸的共轭碱基，n为0或1，X'是卤素；b）将第一混合物与保护化合物反应以获得含有4的第二混合物；c）可选地将第二混合物经结晶、色谱或萃取处理以获得4。
• Aryl phosphate derivatives of d4T having activity against resistant HIV strains
  申请人：——

  公开号：US20040087549A1

  公开（公告）日：2004-05-06

  Methods of inhibiting virus replication of in a cell infected with a resistant strain of HIV that includes administering to the infected cell a virus replication inhibiting amount of an aryl phosphate derivative of d4T.

  抑制HIV耐药株感染细胞中病毒复制的方法包括向感染细胞内施加一定量的d4T的芳基磷酸酯衍生物，以抑制病毒复制。
• NUCLEOSIDE PHOSPHORAMIDATES
  申请人：Ross Bruce S.

  公开号：US20110251152A1

  公开（公告）日：2011-10-13

  Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.

  本文披露了核苷酸磷酰胺及其作为治疗病毒性疾病的药物的用途。这些化合物是RNA依赖性RNA病毒复制的抑制剂，可用作HCV NS5B聚合酶的抑制剂，用于抑制HCV复制并治疗哺乳动物的丙型肝炎感染。